A Phase 1b/2 Dose Escalation and Expansion Study of STC-15, a METTL3 Inhibitor, in Combination with Toripalimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors

Mohamed Salkeni¹, Kyriakos P. Papadopoulos², Nicholas Hornstein³, Melinda Snyder⁴, Gerald McMahon⁴, Marguerite A. Hutchinson⁴, Eric S. Martin⁴, Yaara Ofir-Rosenfeld⁴, Atif Abbas⁴

¹Next Oncology Virginia, Fairfax VA, US; ² START San Antonio, TX, US; ³ Northwell Health, New York, NY, US; ⁴ STORM Therapeutics Ltd., Cambridge, UK

Download poster